Drug Profile
AG 80308
Alternative Names: AG-80308; AGN 232411; AGN-411Latest Information Update: 21 Jun 2023
Price :
$50
*
At a glance
- Originator Allergan
- Developer AbbVie; Allgenesis Biotherapeutics
- Class Anti-inflammatories; Eye disorder therapies; Peptides
- Mechanism of Action Formyl peptide receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Dry eyes
- Preclinical Ocular inflammation
Most Recent Events
- 19 Jun 2023 Efficacy and adverse events data from a phase Ib trial in Dry eyes released by Allgenesis Biotherapeutics
- 19 Jun 2023 Allgenesis Biotherapeutics plans a phase II trial for Dry eyes in the first quarter of 2024
- 02 Nov 2022 Allgenesis Biotherapeutics completes a phase I trial for Dry eyes in USA (Ophthalmic) (NCT05372107)